Table 2 Gain of significance in enriched pathways
From: Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition
PW | |||
Up-regulated | Down-regulated | ||
Pathway | Delta | Pathway | Delta |
protein folding | 5.77 | DNA packaging complex | 3.76 |
‘de novo’ protein folding | 5.73 | basement membrane | 3.47 |
unfolded protein binding | 5.54 | positive regulation of epithelial cell proliferation | 2.52 |
chaperone-mediated protein folding | 5.32 | negative regulation of gliogenesis | 2.49 |
‘de novo’ posttranslational protein folding | 4.68 | fatty acid beta-oxidation | 2.30 |
heat shock protein binding | 4.34 | nucleosome | 2.18 |
response to unfolded protein | 4.10 | glomerulus development | 2.16 |
response to topologically incorrect protein | 3.53 | aorta development | 2.06 |
oxidoreductase activity, acting on paired… | 2.74 | endothelium development | 1.95 |
NBB | |||
Up-regulated | Down-regulated | ||
Pathway | Delta | Pathway | Delta |
positive regulation of cardiac muscle tissue dev… | 1.99 | tertiary granule | 5.22 |
regulation of smooth muscle cell differentiation | 1.98 | ficolin-1-rich granule membrane | 5.00 |
negative regulation of protein serine/threonine kin… | 1.98 | regulation of myeloid leukocyte mediated immunity | 4.55 |
hormone-mediated signaling pathway | 1.95 | regulation of leukocyte degranulation | 4.34 |
lung alveolus development | 1.71 | specific granule | 4.22 |
positive regulation of striated muscle tissue dev… | 1.69 | ficolin-1-rich granule | 4.15 |
positive regulation of muscle organ development | 1.69 | tertiary granule membrane | 3.57 |
positive regulation of muscle tissue development | 1.62 | regulation of mast cell activation | 3.52 |
negative regulation of MAP kinase activity | 1.48 | vacuolar lumen | 3.05 |
regulation of cardiac muscle cell differentiation | 1.48 | regulation of mast cell degranulation | 3.05 |